logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5137.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5137.produseast1
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial | Conference Material / Video | MSF Science Portal
Conference Material
|Video

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A
Similar Content
Slide Presentation
|Slide Presentation
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Abstract
|Abstract
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Loading...

Countries

Ethiopia Kenya Uganda Sudan

Subject Area

neglected tropical diseaseskala azar

Languages

English
DOI
10.57740/a51f-3605
Published Date
07 Jun 2023
Conference
MSF Scientific Day International 2023
Linked Content
Conference Material
|Slide Presentation
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023
Conference Material
|Abstract
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023 June 07 • MSF Scientific Day International 2023